Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyKaiser Permanente radiopharmaceuticals Coverage Up…
    Ask Trek AI about this page
    ModifiedKaiser PermanentePolicy N/A

    Clinical Review Criteria — Radiopharmaceuticals (Lutathera and Pluvicto)

    Customize your policy alerts

    Sign up for all Kaiser Permanente policy alerts

    Know when Kaiser Permanente releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical review criteria governing medical necessity determinations for Lutathium Lu 177 dotatate (Lutathera) for somatostatin receptor‑positive GEP‑NETs and Lutetium Lu 177 vipivotide tetraxetan (Pluvicto) for metastatic castration‑resistant prostate cancer, for use by Kaiser Foundation Health Plan of Washington providers and members.

    Policy Summary
    PayerKaiser Permanente
    PolicyClinical Review Criteria — Radiopharmaceuticals (Lutathera and Pluvicto)
    Policy CodePolicy N/A
    Change TypeMaterial update — hybrid medical necessity criteria added for Pluvicto
    Effective DateDec 1, 202614d
    Last ReviewDec 1, 202614d
    Next Review DateN/A
    Key ActionIf Pluvicto initial criteria are met, authorize 4 doses; if renewal criteria are met, authorize 2 additional doses (total >6 doses investigational).
    SourceLink
    POLICY UPDATE CHANGES

    MPC approved to adopt hybrid medical necessity criteria for Lutetium Lu 177 vipivotide tetraxetan (Pluvicto); effective 12/01/2026.

    Updated radiologic response language with parentheticals to clarify intent under renewal criteria.

    4 dosesInitial Lutathera regimen approvals
    4–6 cyclesPluvicto dosing interval
    Approve x2 doses

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Pluvicto renewal approval
    6 dosesMaximum Pluvicto doses (FDA)
    5RCTs informing evidence
    1,142mCRPC patients in RCTs (safety)

    Coverage Criteria for Radiopharmaceutical Therapies

    inv-01: Lutathera (Dotatate) — Non-Medicare initial criteria

    Candidates must meet ALL of the following:

    Lutathera initial criteria: 1. Presence of metastasized or locally advanced, unresectable (with curative intent) gastroenteropancreatic neuroendocrine tumors (GEP-NET). 2. Ki-67 protein ≤ 20% (patients with higher-grade disease evaluated case-by-case). 3. Progressive disease while on somatostatin analog therapy (SSA). 4. Age ≥ 18 years. 5. Target lesions overexpress somatostatin receptors on 68Ga‑DOTATATE PET/CT within the last 3 months. 6. Monitoring laboratory tests performed per schedule: baseline within 4 weeks prior to first injection; 4–6 weeks after each Lutathera injection; and 2 days prior to subsequent injections.

    inv-02: Lutathera — Contraindications / Not covered conditions

    Contraindications: Women who are or may be pregnant; women who are breastfeeding; pediatric patients (<18 years); recent surgery, radioembolization, chemoembolization, radiofrequency ablation, or chemotherapy within 4 weeks prior to initiation of Lutathera; known brain metastases unless treated and stabilized; uncontrolled congestive heart failure (NYHA II–IV); inability to interrupt short-acting SSA for 24 hours or long-acting (LAR) SSA for at least 4 weeks prior to initiation; prior external beam radiation to >25% of bone marrow; current spontaneous urinary incontinence making administration unsafe.

    inv-03: Pluvicto (Vipivotide Tetraxetan) — Initial criteria

    Lutetium Lu 177 vipivotide tetraxetan is considered medically necessary when ALL of the following are met:

    Pluvicto initial criteria: 1. Age ≥ 18 years. 2. Baseline CT and/or bone scan of chest/abdomen/pelvis within the prior 2 months demonstrating at least one visible lesion. 3. Prior treatment with ≥1 androgen-receptor pathway inhibitor (e.g., enzalutamide and/or abiraterone). 4. Prior receipt of ≥1 taxane-based chemotherapy regimen for mCRPC for at least 2 cycles. 5. PSMA-positive mCRPC defined as at least one tumor lesion with uptake greater than normal liver within the past 3 months. 6. No PSMA-negative prostate cancer lesions exceeding size criteria: visceral ≥1 cm; lymph node ≥2.5 cm; bone ≥1 cm. 7. At least 30 days since starting bisphosphonate or denosumab, if applicable. 8. No radium-223 within the last 6 months. 9. No chemotherapy, immunotherapy, or biologics within 28 days of treatment.

    inv-04: Pluvicto — Diagnostic/lab and performance requirements

    Laboratory and performance status: Prior CNS metastases acceptable if stable and not on steroids for CNS metastases; no NYHA class 3–4 heart failure; no active hepatitis B or C; no uncontrolled infection; birth control required if partner has child‑bearing potential. Laboratory thresholds: WBC ≥ 2.5 K/µL and/or ANC ≥ 1.5 K/µL; hemoglobin > 9 g/dL (no transfusion within 30 days); platelets > 100 K/µL; total bilirubin < 1.5× ULN (≤3× ULN for Gilbert's); AST/ALT < 3× ULN (≤5× ULN if liver metastases present); serum creatinine < 1.5× ULN and creatinine clearance > 50 mL/min (Cockcroft‑Gault with actual body weight); albumin > 3.0 g/L; ECOG performance status 0–2 (PS2 considered carefully).

    inv-05: Pluvicto — Approval and renewal logic

    Approval and renewal: If initial criteria are met, approve 4 doses. Renewal requires the patient has tolerated the medication and demonstrated evidence of response, defined as at least one of: PSA response; radiologic response on CT and nuclear medicine bone scan; or clinical benefit per the treating physician. If renewal criteria are met, approve 2 additional doses. Total treatment exceeding 6 doses is considered investigational and is not approved.

    inv-06: Agent-specific Evidence Summaries

    Evidence summaries and conclusions for specific radiopharmaceutical agents

    177-Lu PRLT evidence: Low‑certainty evidence from randomized trials and multiple observational studies: observational series (n=5,291 mCRPC patients) reported PSA declines in 55.5%–84.7%, partial responses 0%–73%, stable disease 8.4%–46%, OS median ~6–18 months and PFS median ~3.8–11 months. Safety signals across 5 RCTs (n=1,142) and observational studies include grade ≥3 anemia, bone marrow suppression, pain, thrombocytopenia, AST/ALT increases, renal toxicity, and other adverse events; evidence certainty downgraded for heterogeneity and study design limitations.evidence certainty: low

    Heterogeneity, lack of masking, and limited between-group statistical analyses downgraded certainty.

    225-Ac PRLT evidence: Very‑low‑certainty evidence from a single retrospective non‑comparative study (n=40) reporting PSA decreases, median OS >12 months, radiologic PFS ≈6 months, and xerostomia/loss of taste; confidence very low due to small retrospective design.evidence certainty: very low

    Single small retrospective study without comparative data.

    Per policy, Pluvicto (Lutetium Lu 177 vipivotide tetraxetan) treatment beyond a total of 6 doses as specified in the FDA-approved regimen is considered investigational and will not be authorized.

    Some CPT/HCPCS codes may have been deleted or may not be in effect at the time of service; such codes may not be covered. Providers should verify current code status and plan-specific authorization requirements using the Pre-authorization Code Check before submitting requests.

    Lutathera therapy is not covered when any of the listed contraindications or exclusion conditions are present. Examples include women who are pregnant or breastfeeding, pediatric patients (<18 years), recent major procedures or loco-regional therapies or chemotherapy within 4 weeks prior to initiation, known untreated brain metastases, uncontrolled congestive heart failure (NYHA II–IV), inability to interrupt somatostatin analog therapy as specified, prior external beam radiation to more than 25% of the bone marrow, or current spontaneous urinary incontinence that makes administration unsafe.

    The available evidence for lutetium-based PRLTs has important limitations. Overall certainty is rated low to very low because many data come from retrospective or noncomparative observational studies and a small number of randomized trials. Observational series show variable PSA declines and response rates, and RCTs and cohort studies exhibit heterogeneity in populations and protocols, limited masking, small sample sizes, and in several trials lack of between-group comparative analyses—factors that reduce confidence in efficacy and safety estimates.

    Billing and Coding

    Applicable HCPCS Codes (considered medically necessary when criteria met)HCPCSCovered
    A9513Lutetium Lu 177, dotatate, therapeutic, 1 mCi
    A9607Lutetium Lu 177 vipivotide tetraxetan, therapeutic, 1 mCi
    Authorization verification — Pre-authorization Code Check
    ActionUse the Pre-authorization Code Check to verify authorization requirements for the specific CPT/HCPCS code and member plan before submitting the request.
    When to verifyBefore initiating treatment or billing for A9513 (Lutetium Lu 177 dotatate) or A9607 (Lutetium Lu 177 vipivotide tetraxetan).
    ReasonCodes deleted or not in effect at time of service may not be covered; plan-specific authorization rules apply.
    Where to find toolPre-authorization Code Check as referenced in the Applicable Codes section of the policy.

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Pluvicto prior authorization and approval quantities

    If initial Pluvicto criteria are met, approve four doses. If renewal criteria are met (patient tolerated medication and demonstrated evidence of response by PSA response OR radiologic response on CT and NM bone scan OR clinical benefit per treating physician), approve two additional doses. Total treatment greater than six doses is considered investigational and not approved.

    • Initial approval: 4 doses
    • Renewal approval (if renewal criteria met): 2 doses
    • Maximum total doses per FDA regimen: 6 (>6 investigational)
    Billing Rule

    Pre-authorization required for listed HCPCS codes

    Background and Context

    Gastroenteropancreatic neuroendocrine tumors (GEP‑NETs) are uncommon but appear to be rising in incidence. Initial systemic therapy typically uses somatostatin analogs (SSA), and treatment options beyond first-line therapy are limited. Lutathera (Lutetium Lu 177 dotatate) is a radiolabeled somatostatin analog administered as four infusions (the initial regimen) and is indicated for somatostatin receptor–positive GEP‑NETs when patients meet the policy criteria.

    Definitions and Key Terms

    Lutathera (Lutetium Lu 177 dotatate)
    AgentLutathera (Lutetium Lu 177 dotatate): a radiolabeled somatostatin analog that binds somatostatin receptors on tumor cells and delivers beta- and gamma-radiation.
    Indication (per policy)FDA-approved for somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults.
    Dosing scheduleAdministered as four infusions separated by eight-week intervals.
    Radiation characteristicsDelivers beta- and gamma-radionuclides with a maximum particle range of ~2 mm and a half-life of ~160 hours.
    Pluvicto (Lutetium Lu 177 vipivotide tetraxetan)
    AgentPluvicto (Lutetium Lu 177 vipivotide tetraxetan; formerly 177Lu-PSMA): a PSMA-targeted radioligand therapy for metastatic castration‑resistant prostate cancer.

    Revision History

    Policy Summary
    PayerKaiser Permanente
    PolicyClinical Review Criteria — Radiopharmaceuticals (Lutathera and Pluvicto)
    Policy CodePolicy N/A
    Change TypeMaterial update — hybrid medical necessity criteria added for Pluvicto
    Effective DateDec 1, 202614d
    Last ReviewDec 1, 202614d
    Next Review DateN/A
    Key ActionIf Pluvicto initial criteria are met, authorize 4 doses; if renewal criteria are met, authorize 2 additional doses (total >6 doses investigational).
    SourceLink
    On This Page
    Coverage Criteria for Radiopharmaceutical TherapiesBilling and CodingProvider Actions, Prior Authorization, and DocumentationBackground and ContextDefinitions and Key TermsRevision History
    131-I-MIP-1095 PRLT evidence: Very‑low‑certainty evidence from a single retrospective non‑comparative study (n=34) reporting PSA decreases, median time to PSA progression 75 days, median OS ~17 months, and adverse events including fatigue, leukopenia, thrombopenia, and xerostomia; confidence very low due to limited data.evidence certainty: very low

    Single small retrospective study without long‑term follow‑up or comparative data.

    Pre-authorization is required for the listed HCPCS codes when criteria are met; providers must verify authorization requirements for a specific code and plan via the Pre-authorization Code Check.

    • A9513 — Lutetium Lu 177, dotatate, therapeutic, 1 mCi
    • A9607 — Lutetium Lu 177 vipivotide tetraxetan, therapeutic, 1 mCi
    Step Therapy

    Lutathera step therapy requirement

    Lutathera candidates must have progressive disease while on somatostatin analog therapy (SSA) and SSA must be interrupted per protocol prior to administration (short-acting SSA stopped 24 hours before; LAR SSA interrupted at least 4 weeks prior; short-acting SSA may be used as a bridge but stopped 24 hours before treatment).

    • Progressive disease on SSA required
    • Interrupt short-acting SSA ≥24 hours before Lutathera
    • Interrupt long-acting (LAR) SSA ≥4 weeks before initiation
    • Short-acting SSA may be used as bridge but stopped 24 hours before treatment
    Note

    Step therapy / sequencing note

    Revision history documents that the medical policy committee approved adoption of hybrid medical necessity criteria for Pluvicto (Lutetium Lu 177 vipivotide tetraxetan); see revision history for sequencing and step therapy adoption details.

    • 07/07/2026: MPC approved to adopt hybrid medical necessity criteria for Pluvicto; effective 12/01/2026
    • Revision history notes clarifications to renewal radiologic response language
    Documentation Required

    Lutathera required documentation

    Document metastatic or locally advanced unresectable GEP‑NET, Ki‑67 ≤20% (patients with higher-grade disease evaluated case-by-case), progressive disease on somatostatin analog therapy, age ≥18, and somatostatin receptor overexpression on 68Ga-DOTATATE PET/CT within the prior 3 months; monitoring labs must be performed at baseline within 4 weeks, 4–6 weeks after each injection, and 2 days prior to subsequent injections.

    • Diagnosis: metastatic or locally advanced unresectable GEP‑NET
    • Ki‑67 protein ≤20% (higher-grade evaluated case-by-case)
    • Evidence of progressive disease on SSA
    • Age ≥18 years
    • 68Ga-DOTATATE PET/CT showing somatostatin receptor overexpression within 3 months
    • Monitoring labs: baseline within 4 weeks; 4–6 weeks after each injection; 2 days prior to subsequent injections
    Documentation Required

    Pluvicto required documentation

    For Pluvicto, provide baseline CT and/or bone scan of chest/abdomen/pelvis within the prior 2 months showing at least one visible lesion, and a PSMA PET within the past 3 months demonstrating at least one lesion with uptake greater than normal liver; document required laboratory thresholds and ECOG performance status per criteria.

    • Baseline CT/bone scan of chest/abdomen/pelvis within prior 2 months with ≥1 visible lesion
    • PSMA PET within past 3 months with ≥1 lesion uptake > normal liver
    • Document labs (WBC, ANC, Hgb, platelets, bilirubin, AST/ALT, creatinine/CrCl, albumin) and ECOG PS 0–2
    Documentation Required

    Authorization verification and code documentation

    Verify authorization requirements for the specific code and plan using the Pre-authorization Code Check, and document the CPT/HCPCS code(s) used for the service (e.g., A9513, A9607).

    • Use Pre-authorization Code Check to confirm authorization requirements by plan
    • Document HCPCS codes A9513 or A9607 as applicable
    Denial Risk

    Lutathera coverage exclusions

    Lutathera is not covered if the patient had recent surgery, radioembolization, chemoembolization, radiofrequency ablation, or chemotherapy within 4 weeks prior to initiation; other exclusions include untreated brain metastases, uncontrolled CHF (NYHA II–IV), inability to interrupt SSA as specified, prior external beam radiation to >25% of bone marrow, and current spontaneous urinary incontinence making administration unsafe.

    • No recent (within 4 weeks) surgery, radioembolization, chemoembolization, radiofrequency ablation, or chemotherapy
    • No known brain metastases unless treated and stabilized
    • No uncontrolled CHF (NYHA II–IV)
    • Must be able to interrupt SSA per protocol
    • No prior external beam radiation to >25% of bone marrow
    • No current spontaneous urinary incontinence that makes administration unsafe
    Denial Risk

    Pluvicto initial criteria failure

    Do not approve Pluvicto if the initial criteria are not met — examples include age <18, no baseline CT/bone scan within prior 2 months, no prior androgen‑receptor pathway inhibitor, no prior taxane chemotherapy, absence of a PSMA‑positive lesion (uptake greater than liver), or presence of PSMA‑negative lesions exceeding size criteria.

    • Age <18 years — not approved
    • No baseline CT/bone scan of chest/abdomen/pelvis within prior 2 months showing a visible lesion
    • No prior androgen‑receptor pathway inhibitor treatment
    • No prior taxane-based chemotherapy for mCRPC (≥2 cycles)
    • No PSMA-positive lesion with uptake > normal liver within past 3 months
    • PSMA‑negative lesions exceeding size criteria (visceral ≥1 cm; lymph node ≥2.5 cm; bone ≥1 cm)
    Denial Risk

    Denial risk for unsupported codes

    Lack of documentation that the requested HCPCS/CPT code(s) meet the applicable policy statements (e.g., for A9513 or A9607) may result in claim or authorization denial; verify policy criteria and pre-authorization requirements before billing.

    • Failure to meet applicable policy statements for A9513 or A9607 may trigger denial
    • Verify criteria and pre-authorization requirements prior to submission
    Typical regimenGiven every 6 weeks for 4–6 cycles as described in the policy.
    Key eligibility noteRequires PSMA-positive disease (≥1 lesion with uptake greater than normal liver) and prior AR-pathway inhibitor and taxane chemotherapy per policy criteria.
    ECOG Performance Status
    DefinitionECOG Performance Status: a standard measure of patient functional status referenced in guidelines and studies relevant to treatment selection.
    Scale used in policyECOG performance status 0–2 accepted for Pluvicto (PS 2 considered carefully).
    SourceEastern Cooperative Oncology Group (ECOG) performance status reference cited in policy references.